Interlukin-6 (IL-6) is a pleitropic cytokine that plays a central role in normal and abnormal hepatic function and response. The aims of the current study were to determine the viability of using cell encapsulation technology to introduce a genetically modified xenogeneic (CHO) cell population to elevate circulating levels of rhIL-6 in a rat model and determine the effects of sustained high rhIL-6 levels on hepatocellular carcinoma (HCC) progression in vivo. An alginate matrix was combined with transfected CHO cells, selected for their ability to synthesize rhIL-6, and used to generate uniform alginate-cell beads. Once encapsulated transfected cells continued to undergo replication, formed colonies within the bead, and synthesized/released large quantities of rhIL-6 into culture medium in vitro. Intraperitoneal implantation of beads into rats resulted in significantly increased circulating and intrahepatic levels of rhIL-6 up to 4 days postimplantation. Prolonged implantation led to the escape of CHO cells from the bead, resulting in a host response and CHO cell death within the bead. Subsequently CHO-IL-6 encapsulated cells were implanted into rats previously inoculated intrahepatically with the H4IIE HCC cell line. These studies demonstrated the maintenance of high circulating/intrahepatic rhIL-6 levels in this model. Despite significantly increased rhIL-6, this technique did not significantly alter the rate of net tumor progression. However, Stat3 activity was significantly increased in both normal liver and HCC tissue resected from animals implanted with CHO-IL-6 cells. Collectively these data demonstrate the short-term viability of using cell encapsulation technology to generate high levels of active circulating and intrahepatic cytokines and raise the possibility of modifying specific signal transduction cascades identified to be important during tumor progression.
INTRODUCTION
hepatomegaly and hyperplasia in a murine model in which systemic IL-6 levels are raised to supraphysiological levels (42) . These data raise the possibility that Interleukin-6 (IL-6) is a pleiotropic cytokine with diverse biological functions (16) . Within the liver IL-6 has chronic systemic IL-6 administration may act to inhibit HCC progression while simultaneously promoting norbeen identified as a critical cytokine during normal liver development and protection against various forms of mal, nontransformed hepatic cell growth and/or function in vivo. However, systemically administered cytokines liver injury (11) . IL-6 is also central to stimulating the acute phase response (APR) and successful liver regencannot be delivered orally and typically have short halflives in vivo. [
125 I]IL-6 injected into rats is cleared with eration following hepatic insult (29) . Previous studies by our group and others have demonstrated that IL-6 inhiba plasma half-life of approximately 2 min (3). Alternatively, the use of osmotic minipump systems to deliver its hepatocellular carcinoma (HCC) growth in vitro (20, 25) . Conversely, we have demonstrated pronounced cytokines over prolonged periods raises the risks of not attaining sufficiently high circulating cytokine levels studies. All experiments were approved by the Institutional Animal Care & Use Committee and conform to coupled with potential protein degradation in the pumps over time. As such, current techniques of systemic cytoFederal Care and Use of Laboratory Animals guidelines. kine delivery can prove difficult and expensive to maintain in vivo.
Materials Microencapsulation of cells engineered to secrete cyAlpha's modification of minimum essential media tokines and their implantation in animals offers an alter-(αMEM) and dialyzed fetal bovine serum (FBS) were native, sustainable method of cytokine delivery in vivo.
purchased from Biosource (Camarillo, CA). An ELISA The principle of microencapsulation is to create a physikit against human IL-6 was purchased from R&D Syscal, semipermeable barrier between encapsulated cells tems (Minneapolis, MN). Pronova ultrapure sodium aland the host immune system. This membrane allows difginate LVG (75-200 kDa) was purchased from Pronova fusion of oxygen and nutrients to the encapsulated cells (Drammen, Norway). R3603 Tygon tubing and Cytostir while preventing contact with host immune cells and culture flasks were purchased from Fisher Scientific large molecules such as immunoglobulins (39). Algi-(Pittsburgh, PA). Polypropylene mesh filters were purnate, an unbranched polysaccharide, is used extensively chased from Spectrum Laboratories (Rancho Dominfor the encapsulation of many cell types. Alginate is guez, CA). A PHD2000 syringe pump was purchased composed of 1,4-linked α-L-guluronic acids (G) and β-from Harvard Apparatus (Holliston, MA). Millex 0.2 D-mannuronic acids (M) that cross-link on contact with µm vent air filter units were purchased from Millipore divalent cations (such as Ba 2+ and Ca
2+
) to form a gel (Bedford, MA). Coaxial spray atomizer was purchased matrix (39).
from Spraying Systems (Wheaton, IL). The live/dead viEncapsulated cells have previously been used to deability/cytotoxicity kit was purchased from Molecular liver bioactive therapeutic substances in vivo including Probes (Eugene, OR). Antisera specific against gp130, Factor IX (17), parathyroid hormone (15) , and dopamine IL-6Rα, IL-6, PCNA, ERK2, and STAT3 were pur-(1). In addition, encapsulated allogeneic and xenogeneic chased from Santa Cruz Biotechnology (Santa Cruz, pancreatic islets have been used to establish normogly-CA). Antisera specific against pSTAT3 (Tyr705) and cemia in diabetic rodents (27), dogs (34), monkeys (36), p42/44 MAPK were purchased from Cell Signaling and in a human diabetic patient (35) . In regard to cancer Technology (Beverly, MA). All other chemicals used therapy, alginate encapsulation has been utilized as a were purchased from Sigma Aldrich (St. Louis, MO). method to deliver antiangiogenic factors (such as endostatin and angiostatin) using encapsulated, genetically HCC Cell Culture and Animal Model of HCC modified cells. This technique resulted in decreased tumor volume and increased survival in the treatment of
The rat H4IIE hepatoma cell line used in these studies was originally derived from the Reuben-35 hepatoma rat glioma (30) and murine melanoma (6). Similarly, microencapsulated cells expressing iNOS have been used and was purchased from ATCC (Bethesda, MD). For in vitro propagation, H4IIE cells were cultured in αMEM to suppress tumor growth of colon and ovarian carcinomas in vivo (41) while microencapsulated, genetically supplemented with FBS (10%) and antibiotics as previously described (22) . To generate the in vivo model of engineered myoblasts expressing IL-2 (linked to the Fv region of a humanized antibody with affinity to tumors HCC H4IIE cells (Ϸ1 × 10 6 cells) were suspended in 0.1 ml PBS and inoculated directly into the right hepatic overexpressing the oncogene ERB2/HER2/NEU) have also been employed in directed suppression of tumor lobe of male ACI rats. Animals were sacrificed 14 days later and blood and hepatic tissue harvested for analysis growth (5).
The aim of the current study was to determine if the (22) . To perform histological analysis hepatic tissue was collected from sham-operated normal liver, normal liver microencapsulation of genetically manipulated Chinese hamster ovary (CHO) cells that had been altered to overfrom the non-tumor-burdened lobe of HCC animals and HCC/normal liver margin and fixed in paraformaldeexpress recombinant human IL-6 (rhIL-6) would impact cell viability and ability to express rhIL-6 in vitro. Using hyde. Tissues were sectioned and processed for H&E staining. Sections were then examined blindly by mithis technique we next sought to establish the efficacy of this technique to deliver sustainable circulating levels croscopy for the presence of visible lesions/HCC foci in 20 separate fields from the normal liver samples and of IL-6 in vivo and determine the effects of rhIL-6 on hepatic tumor progression in a rat model of HCC.
the HCC specimen analyzed. These studies confirm the absence of HCC cells/metastasis in the normal liver of MATERIALS AND METHODS HCC-burdened animals as well as diminished trabecular Animals structure and increased vascularization of the tumor mass consistent with previous reports from our laboraTwenty-four male ACI rats (Harlan Inc., Indianapolis, IN; 175-200 g, n = 4 per group) were used in these tory and others (1,22,25).
Chinese Hamster Ovary (CHO) Cell Transfection rhIL-6 Enzyme-Linked Immunosorbent Assay (ELISA) and Culture
An ELISA that detects human IL-6 (with lower level of detection >4.7 pg/ml) was performed as per the man-A CHO cell line stably expressing IL-6 was generufacturer's instructions (R&D Systems, Minneapolis, ated by protoplast fusion and propagated in increasing MN). Media samples (250 µl) from cultured CHO cells concentrations of methotrexate to select for amplificaand encapsulated CHO cells were removed sequentially tion of IL-6 cDNA as previously described (19, 40) . The and stored at −20°C prior to analysis. rhIL-6/bead was control cell line used was obtained by transfection with determined by removing beads from stirrer culture and a mammalian expression vector and selection in 0.2 µM plating in six-well plates. The number of beads in the methotrexate. The single clone used in this study (desigaliquot/six-well plate was then counted and rhIL-6 pronated CHO-C) produced no detectable IL-6 as assayed duction in the medium was measured 24 h later. Plasma by ELISA (42) . Following selection CHO cells were rhIL-6 levels were determined by ELISA following cultured in high serum media (HSM) consisting of plasma separation of blood samples. αMEM supplemented with antibiotics, Glutamax (2 mM), methotrexate (0.2 µM), and 10% (v/v) dialyzed Live/Dead Cell Viability Assay FBS at 37°C in a 5% CO 2 humidified incubator.
Cell viability of encapsulated CHO cells was deterAlginate Microencapsulation of CHO Cells mined using a Live/Dead Viability/Cytotoxicity Kit performed as per the manufacturer's instructions. A 1-ml Cultured CHO cells (IL-6 and control) were detached sample of alginate beads was removed from culture and using trypsin and resuspended in PBS prior to addition allowed to settle in an Eppendorf tube for 5 min. Excess to sodium alginate solution [1.7% (w/v) ultrapure somedium was discarded and beads were placed in a fourdium alginate LVG; 75-200 kDa MW range, 0.9% (w/v) well tissue culture plate. Then 250 µl of Live/Dead NaCl, 2.2 mM HEPES, 0. 8mM glucose, pH 7.4] at a working reagent (2 µM Calcein AM, 4 µM EthD-1, density of 1 × 10 6 cells/ml. The alginate-cell suspension PBS) was added and beads were incubated in darkness was then loaded into a 5-ml syringe and mounted on a for 45 min. Beads were visualized using a Fluoview syringe pump and connected to the liquid inlet of the FV500 IX70 confocal laser scanning microscope and coaxial spray atomizer. Beads were then collected in a Fluoview FV500 version 4.3 image processing software 1.5% CaCl 2 (w/v) solution containing 13 mM HEPES at (Olympus America, Melville, NY). a syringe pump rate of 1 ml/min and an air flow rate of 6 L/min with the atomizer 20 cm above the collection Preparation of Tissue Lysates and Immunoblotting solution. Following collection beads were passed Hepatic tissue was collected at sacrifice, grossly disthrough a 500-µm followed by a 300-µm filter system, sected for HCC and normal liver tissue, and snap frozen washed with αMEM, and placed in 100 ml CHO high in liquid nitrogen. Lysates were prepared by placing tisserum [10% (v/v) FBS] medium in a Cytostir stirrer culsue in ice-cold lysis buffer and equalizing for protein ture flask. Beads were then incubated with gentle agitaconcentration as previously described (25) . Immunoblot tion in a 37°C/5% CO 2 humidified incubator; 80% of analysis was performed using 12.5% SDS-PAGE as prethe total medium volume was then replaced every 48 h.
viously described (25) . Primary antibodies were diluted 1:1000 in 5% (w/v) nonfat dry milk in 0.
1% (v/v) Alginate Bead Implantation In Vivo
Tween-20/Tris-buffered saline (TBS) with the exception Alginate beads were removed from stirrer culture and of anti-phospho-STAT3 (1:2000). Signal intensity was allowed to settle in 50-ml sterile tubes for 10 min. Exanalyzed using the Kodak EDAS290 imaging software cess medium was discarded; 250 or 500 µl packed bead (Rochester, NY). volume was placed in 15-ml sterile tubes and washed with αMEM (3×) and PBS (2×). Empty beads (no cells) RESULTS or beads containing either mock-transfected (control) or Synthesis and Release of rhIL-6 Is Maintained rhIL-6-expressing CHO cells were next implanted intraFollowing Cell Encapsulation In Vitro peritoneally into either control (no H4IIE HCC cell inoculation) or HCC (H4IIE HCC cell inoculation) rats 10 ELISA performed on media removed from cultured CHO cells transfected to overexpress rhIL-6 (CHO-IL6) days after H4IIE inoculation using a large orifice, 200-µl Eppendorff pipette tip. Animals were weighed daily or mock transfected (CHO-C) demonstrated no detectable levels of rhIL-6 in CHO-C cells. In contrast, methroughout the time course and sacrificed 14 days post-H4IIE cell inoculation. Blood and hepatic tissue were dium from cultured CHO-IL-6 cells demonstrated rhIL-6 production at a rate of 35.2 ± 5.8 pg/ml rhIL-6/cell/ collected for analysis and peritoneal lavage performed using HSM αMEM to recover implanted beads for viaday (n = 4 separate experiments assayed in triplicate) 3 days after initial cell seeding. This rate of rhIL-6 probility analysis. duction was maintained and did not significantly change postimplantation and that the beads retained their original size, shape, and integrity (Fig. 3d, e) . throughout the remainder of the culture period (7 days).
Alginate encapsulated beads containing CHO-IL-6 or Despite the presence of this fibrotic tissue cell viability remained high 4 days after bead implantation in both CHO-C cells were next generated and, following twostep filtration, demonstrated uniform spherical bead for-CHO-IL6 and CHO-C encapsulated beads, and cells enclosed within the beads retained the ability to form mation (300-500 µm diameter) with uniform CHO cell distribution throughout the bead (Fig. 1a) . Live/dead cell colonies (Fig. 4a, b) . In contrast, the viability of encapsulated cells was significantly compromised in both analysis demonstrated a cell viability of >95% (as assessed by colormetric analysis of green vs. red cells) in CHO-IL-6 and CHO-C beads recovered 7 days after implantation and beads were surrounded by a large number both CHO-C and CHO-IL6 cells following encapsulation/culture (Fig. 1b) that was maintained throughout the of host cells (Fig. 4c) .
To ascertain whether encapsulated cells retained the remainder of the experimental period (Fig. 1b) . Interestingly, 24 h after encapsulation both CHO-C and CHOability to synthesize and release rhIL-6, plasma from bead-implanted animals was collected and analyzed by IL6 cells were evenly dispersed throughout the alginate beads and appeared as single cells (Fig. 1b) . However, ELISA. These data demonstrated detectable levels of rhIL-6 in plasma from CHO-IL6 bead implanted rats 4 with time in culture, both the CHO-C and CHO-IL6 cells began to grow in defined, multicellular colonies days postimplantation but not at 7 days (0.92 ± 0.18 pg/ ml rhIL-6/g rat body weight, n = 4 separate animals, (Fig. 1b) . Sequential ELISA analysis demonstrated no detectable levels of rhIL6 in the media removed from analysis performed in triplicate) (Fig. 5a ). rhIL-6 was not detectable in plasma analyzed from CHO-C-implanted CHO-C encapsulated cells. In contrast, rhIL-6 was readily detectable in the media of CHO-IL-6 beads rebeads at either 4 or 7 days postimplantation (Fig. 5a , n = 4 separate animals, analysis performed in triplicate). moved from culture within 24 h of encapsulation (431.735.2 ± 148.2 pg rhIL-6/bead/day) and increased Doubling the number of implanted CHO-IL-6 beads from 0.25 to 0.5 ml packed bead volume led to an apsignificantly with time of culture, a maximal production of 5494.8 ± 777.8 pg rhIL-6/bead/day being detected 12 proximately fivefold increase in the detection of rhIL-6 in plasma (0.92 ± 0.18 vs. 4.95 ± 0.39 pg/ml/g rat body days after initial encapsulation (Fig. 1c , n = 4 separate experiments assayed in triplicate, p < 0.05 day 1 vs. day 12).
weight, n = 4 separate animals assayed in triplicate, p < 0.05). To confirm bead viability following in vivo imMicroscopic analysis of representative bead structures demonstrated that 7 days after initial encapsulation plantation, CHO-IL-6 beads were collected by peritoneal lavage, resuspended in HSM in culture, and the medium of CHO-IL6 and CHO-C both cell types were observed to "escape" from the confines of the alginate bead maassayed for rhIL-6 production. These data demonstrated significant levels of rhIL-6 released from CHO-IL6 trix (Fig. 2a-c) . Cells that exited the alginate matrix were observed to attach and proliferate on the plastic beads recovered 4 days after implantation (2076 ± 288 pg rhIL-6/bead/day) but failed to detect any rhIL-6 resurface of the tissue culture plates (Fig. 2d) .
leased from beads recovered 7 days after implantation Cell Viability and Ability to Synthesize rhIL-6 (Fig. 5c , n = 4 sets of beads recovered from different Is Maintained In Vivo animals). Encapsulated CHO-IL6 cells produced significantly Effect of Sustained Systemic IL-6 Release on HCC more rhIL-6 following colony formation within the algiProgression In Vivo nate matrix. To maximize potential rhIL-6 synthesis and release in vivo cells were encapsulated and cultured for
The inoculation of H4IIE cells directly into the parenchyma of male ACI rats (175-200 g) resulted in a focal 4 days prior to implantation. Preliminary studies performed on control animals (no H4IIE inoculation) demtumor mass forming 14 days after inoculation (Fig. 6a) . The body weight of the rats in all treatment groups onstrated that after 4 and 7 days of implantation a significant number of beads became surrounded by fibrotic (Control and HCC ± Empty bead, CHO-IL6, or CHO-C encapsulated) did not change significantly over the tissue (Fig. 3a, b) . Live/dead analysis of these fibrous masses demonstrated the presence of a large number of experimental period (data not shown). In contrast liver/ body weight ratio was significantly increased in rats live cells within the fibrous mass (Fig. 3c) . To determine whether the formation of these masses represented a with CHO-IL6 bead implants [37.1 ± 1.7 vs. 31.2 ± 1.4 (empty beads) and 32.8 ± 0.9 (CHO-C) mg liver wt/g host response against the alginate beads per se or, as suspected, against CHO cells/antigens escaping from the body wt, n = 4 per group, p < 0.05]. Analysis of tumor volume (as calculated using the equation to calculate the alginate beads, we next implanted empty alginate beads. These studies demonstrated that, following bead recovvolume of an ellipsoid
demonstrated a high degree of variability within the ery, no fibrous masses were detected either 4 or 7 days same treatment group (e.g., CHO-IL-6 volume range strated significantly decreased gp130 expression in HCC tissue versus NL in all samples analyzed (Fig. 7b) . Howwas 120-945 mm 3 vs. CHO-C 216-1380 mm 3 ) and no significant conclusion could be reached as to the effect ever, implantation of empty beads or beads containing CHO-C or CHO-IL6 cells did not cause any significant of rhIL-6 on net tumor size (Fig. 6c) . difference in gp130 expression between NL or HCC samples in the different treatment groups (Fig. 7b, upper 
Sustained Systemic rhIL-6 Significantly Alters panel). Similarly, IL-6Rα expression was significantly IL-6-Dependent Signaling in a Rat Model of HCC
higher in NL tissue versus HCC tissue in all three treatment groups (Fig. 7b, lower panel) . Densitometric analWestern blot analysis using antibodies specific against rhIL-6 demonstrated detectable levels of rhIL-6 ysis did demonstrate higher IL-6Rα expression in NL from animals receiving CHO-IL-6 alginate beads, alin both HCC and NL from animals implanted with CHO-IL-6 beads (Fig. 7a) . In contrast, no detectable though these differences were not statistically significant versus either empty or CHO-C alginate beads (n = 4 rhIL-6 was detected in either HCC or NL tissue from animals implanted with empty or CHO-C beads (Fig. 7) . separate animals). We next analyzed the expression and activity of Western blot analysis using antibodies specific against IL-6 receptor expression (gp130 and IL-6Rα) demondownstream regulators of IL-6 signaling demonstrated to be important in regulating IL-6-dependent inhibition ment groups (empty, CHO-C, and CHO-IL-6), although no significant differences in pERK1/2 were detected beof HCC growth in vitro (25) . Using antibodies specific against Stat3 and activated Stat3 (pStat3) we demontween HCC. Finally, NL and HCC tissue was analyzed for PCNA expression as a marker of cellular proliferastrated that total Stat3 expression remained constant in NL and HCC tissue regardless of the alginate bead type tion. These data demonstrate detectable PCNA expression in HCC tissue from all three treatment groups implanted (Fig. 7c, upper panel) . In contrast, pStat3 expression was significantly increased in both NL and (empty, CHO-C, and CHO-IL6) and no significant differences between PCNA expression in HCC samples HCC tissue from animals receiving CHO-IL-6 encapsulated cells versus those receiving either empty or CHOfrom these three groups was evident (Fig. 7e ). C beads (Fig. 7c, lower panel) . Furthermore, pStat3 activity was significantly higher in HCC tissue from DISCUSSION CHO-IL-6-implanted animals versus NL tissue (Fig. 7c,  lower panel) . In addition to Stat3, IL-6 has been demonThe use of genetic cell modification to overexpress/ release cytokines has generated considerable interest as strated to regulate ERK-MAPK activity. Analysis of total and active ERK (ERK/pERK) expression demona means to deliver sustained cytokine release in vivo (39). In order to successfully employ encapsulation techstrated significantly higher ERK activity/total ERK expression in HCC tissue versus NL in all three treatnology it is imperative to overcome the problem of host immune response such that implanted cells survive for a tion. Given the unique dual circulation of the liver, in which blood from the gastrointestinal tract is delivered sufficient period of time to synthesize/release the cytokine of interest (39). Microencapsulation represents a to the liver via the hepatic portal vein, and the role of the liver in systemic metabolism and clearance, this means whereby a semipermeable barrier is sufficiently robust to protect transfected cells from the host immune technique may have particular significance in delivering high levels of cytokine to the liver. response yet allows the diffusion of oxygen and nutrients required for cell survival and cytokine release in IL-6 has previously been reported to be a critical cytokine during normal hepatic growth and has been idenvivo. While this technology has been developed and has generated particular interest for use in endocrine distified as a central factor in the acute phase response (APR) during hepatic regeneration (21) . Sustained high eases, to date relatively few studies have considered its use in targeting normal and/or abnormal hepatic funclevels of circulating rhIL-6 have also been reported to drive hepatomegaly and hyperplasia in an immunecrine role for IL-6 in HCC-M hepatoma cell growth (23) and a role during cell survival in Hep3B HCC cell lines compromised murine model (42) . Within the context of HCC the role of IL-6 is less clear. Previous studies have (4) has been reported. In vivo, studies by Reichner et al. demonstrate that overexpression of IL-6 in HCC is demonstrated inhibition of mitogenesis in human and animal HCC cell lines in vitro (25) . In contrast, an autolinked to increased tumor metastatic potential (31), while Kang and colleagues report inhibition of tumor geneic cells and host response. Alternatively, implantation of the beads to other sites in vivo may act to progression following transfection of a murine HCC cell line to overexpress . Similarly, in nonhepatic prolong the longevity of the beads and sustain circulating cytokine levels. For example, subcutaneous bead tumors, IL-6 has been reported to decrease colon tumor metastasis (9,26) and inhibit acute myeloid leukemia deimplantation may result in increased bead viability following implantation. However, this technique requires velopment, possibly via stimulation of the innate immune response (13) . While these data support the use of additional experimentation to determine whether subcutaneous vasculature is sufficient to sustain encapsulated IL-6 as a potential agent in the treatment of a variety of cancers, the administration of sustained high levels of cells and whether an alternative site, such as the omental pouch, may be more appropriate. Alternatively, a recent cytokines is usually expensive and can be limited by the relatively short half-life of IL-6 in the circulation, due study by Halberstadt and colleagues demonstrated the viability of creating a subcutaneous space for cell translargely to hepatic clearance (33) .
Data in the current study using cell encapsulation plantation using a prevascularized device (14) , raising the possibility of using this technique in conjunction techniques in vitro demonstrate sustained cell viability following encapsulation and a retained ability to synthewith cell encapsulation technology. Using the established H4IIE inoculation model of size high levels of rh-IL6 that is released from the alginate bead matrix. Furthermore, prolonged culture of en-HCC (10) in conjunction with CHO-IL6 cell encapsulation we demonstrated increased intrahepatic/tumor rhILcapsulated beads led to the formation/proliferation of cell colonies within the bead, independent of the ability 6 levels and increased Stat3 activity in animals receiving CHO-IL6 cells. However, despite previous studies demto synthesize rhIL-6. While progression of colonies was associated with increased levels of rhIL-6 release, it was onstrating inhibition of H4IIE cell proliferation using rhIL-6 (50 ng/ml) in vitro (25) , sustained rhIL-6 failed also associated with cells escaping the alginate matrix into the culture medium. Following introduction of ento significantly alter the rate of HCC progression in vivo. Several possible explanations exist to explain these capsulated cells into the in vivo environment we demonstrated sustained high levels of circulating rhIL-6 up to observations. The use of in vitro culture techniques enables the manipulation of specific signaling cascades, al-4 days following implantation. However, implantation of beads for 7 days was associated with decreased cell lowing the study of individual components following IL-6R receptor activation. In contrast, the tumor in vivo is viability/CHO cell death and the beads initiating a host response. The host response, due to CHO cell escape/ subjected to the activity of multiple signaling cascades in addition to those activated by high levels of circulatantigen release from the beads, was confirmed by the use of empty beads implanted into the peritoneum that ing rhIL-6. Indeed, the presence of signal transduction cross-talk and processing may have even more profound failed to generate a host response. Previous reports have identified similar problems of cell escape using alginate effects in the tumor-burdened liver given that previous studies have identified difference in cytokine expression beads, particularly when used with proliferating cells due to physical space constraints associated with bead in histologically normal liver resected from the HCCburdened liver versus normal liver from sham-operated size (32) . To address this issue, poly-L-lysine (PLL) coating of beads following cell encapsulation has been animals (28) . In addition, in the clinical setting of HCC, the majority of patients diagnosed have compromised employed to increase the strength of the outer bead surface (38) . These beads can then be further modified by normal hepatic function due to the presence of underlying hepatic cirrhosis (24) . Similarly, the failure to inhibit liquification of the alginate "core" using calcium chelators such as citrate (38) . Similarly, during bead forma-HCC growth using this technique may also be dependent on the time at which animals are inoculated. In the curtion, the use of a low calcium collection solution increases the net bead strength as a result of alginate rent studies limitations in bead viability in vivo (4 days) led us to choose a 10-day time point for inoculation. migration towards the surface of the bead due to its affinity for Ca 2+ ions (38) . Alternatively, the use of Ba
2+
At this point the tumor mass and neovascularization is established and growth is in an exponential phase (in place of Ca 2+ ) strengthens the bead structure due to increased cross-linking within the alginate (12). Simi-(10,22,25). As such it is possible that by this stage of tumor growth the inhibitory effects of IL-6 on tumor cell larly, studies using modified techniques of bead formation have demonstrated the ability to generate beads proliferation are no longer capable of overcoming the promitogenic signaling pathways activated by other cywith molecular weight cutoff points below that of common host IgG proteins (2,7,8). Given the short-term suctokines. Indeed, it will be of considerable interest to determine whether the use of sustained high circulating cess of using the current encapsulation method to elevate circulating/intrahepatic rhIL-6 levels, future work levels of IL-6 are able to inhibit the initial stages of implantation and proliferation in this model of HCC. using modified bead structures should improve the longevity of bead integrity and diminish the escape of xenoIn addition to the role of other signaling cascades in mediating IL-6 responsiveness in vivo, IL-6 signaling demonstrated the ability to increase circulating and intrahepatic rhIL-6 levels and alter the expression and acper se can also be regulated at multiple levels. In the current studies we failed to detect significant changes in tivity of components of IL-6 signaling in vivo. While these studies did not demonstrate significant changes in either gp130 or IL-6Rα expression in lysates prepared from normal and HCC tissue. In addition to this "classithe rate of HCC progression in the current model employed, we believe that future studies in which modificacal" model of receptor activation and downstream signaling, IL-6 can also signal via a soluble form of the ILtion to the encapsulation technology used and changes in the time of implantation may act to significantly alter 6 receptor (sIL-6R) (37) . In this instance, IL-6 binds a soluble form of the α-receptor and this complex is able the rate of tumor formation. These studies may be of particular significance in the analysis of the effects of to activate cells expressing only the gp130 β-receptor. The current study only assessed changes in expression cytokines such as IL-6 that are known to be critical during immune and acute phase responses. In particular, the of membrane integrated IL-6R components and the role of other factors such as soluble receptor isoforms needs current model may demonstrate significant advantages over the use of immune-compromised animals used to to be further studied. In addition, it is of interest to note that doubling the packed bead volume implanted into study tumor growth in vivo and the cost of cytokines used in other protein delivery techniques. animals led to approximately fivefold increases in circulating levels of free rhIL-6. This increase in free rhIL-6
